Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Ipamorelin Review 2026: Dosing & Timing Comparison

Protocol timing and dosing structure determine GH pulse quality and receptor longevity. This table compares common administration patterns based on clinical evidence and real-world application data. Single Daily Dose 200–300mcg Pre-sleep only 15–20 ng/mL Moder

This comparison does not assign a generated winner or score.

  • Protocol timing and dosing structure determine GH pulse quality and receptor longevity. This table compares common administration patterns based on clinical evidence and real-world application data.
  • Single Daily Dose
  • 200–300mcg
  • Pre-sleep only
  • 15–20 ng/mL
  • Moderate. Desensitisation by week 10–12
  • Simplest compliance but suboptimal pulsatility; best for short cycles or new users
  • Twice Daily Split
  • 200–300mcg total
  • Post-training + pre-sleep
  • 18–25 ng/mL per pulse
  • High. Sustainable through 12 weeks
  • Gold standard for body recomposition and recovery; mimics natural GH rhythm
  • Three-Times Daily
  • 300mcg total
  • Morning, post-training, pre-sleep
  • 22–27 ng/mL per pulse
  • Very High. Minimal desensitisation through 12 weeks
  • Optimal for GH-deficient populations or advanced protocols; requires strict timing
  • High-Dose Single Pulse
  • 400–500mcg
  • 28–35 ng/mL initially, drops to 12–15 ng/mL by week 6
  • Poor. Rapid receptor downregulation
  • Not recommended; receptor burnout negates initial benefit
  • Micro-Dose Continuous
  • 50–75mcg
  • Four times daily
  • 8–12 ng/mL per pulse
  • Excellent. No desensitisation observed through 16 weeks
  • Experimental; high compliance burden but preserves sensitivity indefinitely